What the research found

Researchers engineered an enzyme called CMLase that can remove a specific type of age-related damage from proteins. This damage—a chemical modification called carboxymethyl-lysine (CML)—accumulates over decades, particularly in long-lived structural proteins like collagen. CML damages proteins by crosslinking them together, altering their shape, and triggering inflammatory pathways through immune receptors.

The team started with a naturally occurring bacterial enzyme and used directed evolution—exposing bacterial cells to thousands of mutated variants and selecting only those that could reverse the CML modification—to dramatically improve its function. The engineered version successfully removed CML from multiple types of human tissue samples, including lens proteins from a 64-year-old donor, artery tissue (70% reduction in CML), and skin (55% reduction, bringing levels below those seen in 31-year-old skin).

This represents an important shift: protein glycation has historically been considered irreversible. However, the study was conducted on thin tissue sections and extracted proteins rather than intact living tissue, which raises questions about whether the enzyme could actually penetrate and function in the body.

Why it matters for you

If this approach eventually translates to humans, the implications touch on several aspects of what MyKine users monitor. Glycation damage contributes to skin aging, arterial stiffness, and lens clouding—all markers of biological aging you can observe clinically. Reducing CML accumulation could theoretically improve arterial compliance (relevant to cardiovascular biomarkers), skin elasticity, and eye health.

The broader relevance is that most longevity strategies currently focus on slowing AGE accumulation through glucose control, antioxidants, and anti-inflammatory protocols. This research hints at a future where you might reverse existing damage. That's conceptually different from optimising your continuous glucose monitor readings or managing inflammation via peptides and supplements—it's remediation of past accumulated wear.

However, no functional improvements were demonstrated in this study. We don't yet know whether removing CML actually restores protein function or tissue properties in living systems, or whether the enzyme would trigger an immune response in humans.

Caveats

• In vitro and thin-section tissue only. Work was done on extracted proteins and tissue slices, not intact organs or organisms. Enzyme penetration and delivery in living tissue remains unknown.
• No functional rescue data. Removal of CML was chemical, not functional—the study didn't measure whether treated tissues actually worked better (e.g., improved arterial compliance or skin elasticity).
• Immunogenicity untested. A bacterial-derived enzyme may trigger human immune responses; this wasn't assessed.
• Single AGE target. CML is one of many glycation products. Other modifications like glucosepane (which forms crosslinks between collagen molecules) remain unaddressed and may be harder to reverse.
• Variable efficacy. Some CML sites were easier to remove than others; the reasons remain unclear, suggesting site-dependent limitations.
• Early stage. This is proof-of-concept in tissue samples from older donors, not animal models or humans.